Literature DB >> 33547398

Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image.

Mai Hong Son1, Le Ngoc Ha1, Mai Hong Bang2, Sungwoo Bae3,4, Dinh Truong Giang2, Nguyen Tien Thinh2, Jin Chul Paeng5.   

Abstract

99mTc-macroaggregated albumin (MAA) imaging is performed before transarterial radioembolization (TARE), in which SPECT/CT is presumed more precise than planar image. However, additive role of SPECT/CT has not been well established. Thirty-four consecutive hepatocellular carcinoma patients of intermediate and advanced stages who underwent 90Y-microsphere TARE were recruited. On pre-treatment planning scan using 99mTc-MAA, image characteristics and absorbed dose for target tumors calculated by partition model methods were estimated on planar image and SPECT/CT, respectively. The measurements were repeated on post-treatment 90Y PET/CT, as the reference standard. Treatment response was assessed and predictive values of image parameters were analyzed. The image characteristics including heterogeneity, necrosis and thrombosis uptake were better delineated on SPECT/CT than planar scan. The agreement and correlation of TNr between SPECT/CT and PET/CT were stronger than those between planar scan and PET/CT. Tumor dose estimated on 99mTc-MAA SPECT/CT was more effective than planar image for prediction of treatment response, with cutoff value 125 Gy (sensitivity of 86% and specificity of 75%). In conclusion, 99mTc-MAA SPECT/CT is more closely correlated with post-treatment 90Y PET/CT, and is more effective for predicting treatment response than planar scan. SPECT/CT is superior to planar image in simulation before 90Y TARE.

Entities:  

Year:  2021        PMID: 33547398      PMCID: PMC7864932          DOI: 10.1038/s41598-021-82887-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  32 in total

1.  The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.

Authors:  Hojjat Ahmadzadehfar; Amir Sabet; Kim Biermann; Marianne Muckle; Holger Brockmann; Christiane Kuhl; Kai Wilhelm; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

2.  Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations.

Authors:  Lidia Strigari; Rosa Sciuto; Sandra Rea; Livio Carpanese; Giuseppe Pizzi; Antonella Soriani; Giuseppe Iaccarino; Marcello Benassi; Giuseppe Maria Ettorre; Carlo Ludovico Maini
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

Review 3.  Radioembolization dosimetry: the road ahead.

Authors:  Maarten L J Smits; Mattijs Elschot; Daniel Y Sze; Yung H Kao; Johannes F W Nijsen; Andre H Iagaru; Hugo W A M de Jong; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  Cardiovasc Intervent Radiol       Date:  2014-12-24       Impact factor: 2.740

Review 4.  Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction.

Authors:  Riad Salem; Kenneth G Thurston
Journal:  J Vasc Interv Radiol       Date:  2006-10       Impact factor: 3.464

5.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  Francesco Giammarile; Lisa Bodei; Carlo Chiesa; Glenn Flux; Flavio Forrer; Françoise Kraeber-Bodere; Boudewijn Brans; Bieke Lambert; Mark Konijnenberg; Françoise Borson-Chazot; Jan Tennvall; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

Review 6.  Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.

Authors:  Ahsun Riaz; Robert J Lewandowski; Laura M Kulik; Mary F Mulcahy; Kent T Sato; Robert K Ryu; Reed A Omary; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2009-07-29       Impact factor: 3.464

7.  Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin.

Authors:  S Ho; W Y Lau; T W Leung; M Chan; K W Chan; W Y Lee; P J Johnson; A K Li
Journal:  Br J Radiol       Date:  1997-08       Impact factor: 3.039

Review 8.  The role of SPECT/CT in radioembolization of liver tumours.

Authors:  Hojjat Ahmadzadehfar; Heying Duan; Alexander R Haug; Stephan Walrand; Martha Hoffmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

Review 9.  Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.

Authors:  Mi Na Kim; Beom Kyung Kim; Kwang-Hyub Han; Seung Up Kim
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-11-05       Impact factor: 3.869

Review 10.  Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.

Authors:  Etienne Garin; Yan Rolland; Sophie Laffont; Julien Edeline
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

View more
  2 in total

Review 1.  Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma.

Authors:  Zersenay Alem; Timothy E Murray; Csilla Egri; John Chung; David Liu; Khaled M Elsayes; Silvia D Chang; Alison Harris
Journal:  Abdom Radiol (NY)       Date:  2021-04-28

Review 2.  Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.

Authors:  Philippe d'Abadie; Stephan Walrand; Renaud Lhommel; Michel Hesse; Ivan Borbath; François Jamar
Journal:  Curr Oncol       Date:  2022-03-29       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.